Skip to main content
Clinical Trials/NCT02678117
NCT02678117
Completed
Phase 3

Analgesic Potentials of Preoperative Oral Pregabalin,Intravenous Magnesium Sulphate and Their Combination in Acute Post-thoracotomy Pain.(Randomized,Double-Blind Study)

National Cancer Institute, Egypt1 site in 1 country120 target enrollmentJuly 2015

Overview

Phase
Phase 3
Intervention
Pregabalin & Placebo
Conditions
Postoperative Pain
Sponsor
National Cancer Institute, Egypt
Enrollment
120
Locations
1
Primary Endpoint
Total morphine consumption
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

This study evaluates the effect of giving preoperative adjuvant drug as pregabalin or magnesium sulphate or a combination of both drugs to decrease postoperative morphine consumption and pain intensity in the first 24 hours in postoperative period . quarter of patients receive single dose oral pregabalin 300mg 1 hour preoperatively ,other quarter receive single intravenous Magnesium sulphate 50mg per Kg over 200ml saline over 20 minutes preoperatively , other quarter receive combination of both drugs , the last quarter receive placebo drugs . All patients receive 0.1mg per Kg intravenous morphine sulphate intraoperatively

Detailed Description

Magnesium (Mg) acts on N-methyl-D-aspartate (NMDA) receptor as a non-competitive antagonist with antinociceptive effects. Gabapentin is an alkylated analogue of gammaaminobutyric acid (GABA) developed primarily as an anticonvulsant drug. It was described as an analgesic drug for the treatment of neuropathic pain in the 1990s. Although it is named Gabapentin,it does not bind at the GABA A or GABA B receptor. It binds with high affinity for the α2δ subunit of the presynaptic voltage-gated calcium channels, which reduce calcium-dependent release of pro-nociceptive neurotransmitters in the pain pathways. Pregabalin is a structural analogue of GABA was introduced after Gabapentin. If we used these drugs in combination to opioids preoperatively as preventive analgesia may decrease postoperative opioid consumption and pain intensity.

Registry
clinicaltrials.gov
Start Date
July 2015
End Date
December 2019
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
National Cancer Institute, Egypt
Responsible Party
Principal Investigator
Principal Investigator

Ahmed Salah Ahmed Abd Elgalil

Demonstrator in anaesthesia department, National Cancer Institute, Egypt

National Cancer Institute, Egypt

Eligibility Criteria

Inclusion Criteria

  • ASA status of1 or 2
  • Patients undergoing thoracotomy
  • Body mass index (BMI): Less than forty and more than twenty.

Exclusion Criteria

  • Known sensitivity or contraindication to drugs used in the study.
  • History of psychological disorders and/or chronic pain.
  • Patients receiving medical therapies that are considered to result in tolerance to opioids.
  • Significant liver or kidney diseases that will affects the pharmacokinetics of study drugs.

Arms & Interventions

Pregabalin & placebo

: will receive single dose oral Pregabalin 300 mg one hour preoperative and 200 ml of normal saline over 20 min.

Intervention: Pregabalin & Placebo

Magnesium sulphate & Placebo

will receive preoperative single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline and a placebo capsule similar to pregabalin 300 mg.

Intervention: Magnesium sulphate & Placebo

Pregabalin & Magnesium sulphate

: will receive single dose oral pregabalin 300mg one hour preoperative and single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline.

Intervention: Pregabalin & Magnesium sulphate

Placebo

will receive placebo medications at the same time and route of administration of other groups.

Intervention: Placebo

Outcomes

Primary Outcomes

Total morphine consumption

Time Frame: First 24 hours in postoperative period

patients are given regular intravenous morphine through patient controlled analgesia (PCA) and morphine consumption calculated from the PCA device

Secondary Outcomes

  • Pain intensity using Visual Analogue Scale(First 24 hours in postoperative period)
  • Heart Rate(First 24 hours in postoperative period)
  • Blood Pressure(First 24 hours in postoperative period)
  • Oxygen saturation(First 24 hours in postoperative period)
  • Respiratory Rate(First 24 hours in postoperative period)
  • Recovery Time(Immediately after ending the surgery)
  • Postoperative nausea and vomiting(First 24 hours in postoperative period)
  • Sedation score(First 24 hours in postoperative period)
  • Side effects from the used drugs(First 24 hours in postoperative period)

Study Sites (1)

Loading locations...

Similar Trials